COPENHAGEN, Denmark, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, ...

Monetary policy is forward-looking and dependent on policymakers’ economic outlook. When the outlook is deemed highly uncertain, policymakers may put more weight on incoming data when making monetary ...

Rina-S showed a 50% confirmed response rate in heavily pretreated advanced endometrial cancer patients, with two complete responses observed. The phase 1/2 results support Rina-S as a potential ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, albeit with a high incidence of hematologic toxicity and infections. The ...

TAR-200 achieved an 82.4% overall complete response rate in BCG-unresponsive, high-risk NMIBC patients with CIS, with a 45.9% 12-month complete response rate. The median duration of response was 25.8 ...

Please provide your email address to receive an email when new articles are posted on . Dostarlimab conferred clinical complete responses in all patients treated during a phase 2 trial.. Circulating ...

Over 80% of patients with relapsed/refractory multiple myeloma responded to anti-GPRC5D CAR T-cell therapy after failure of anti-BCMA CAR T-cell therapy. The investigational therapy showed superior ...